Status:
UNKNOWN
CMV IGG Antibodies in Semen as a Predictor for Blood Testis Barrier Damage
Lead Sponsor:
Hadassah Medical Organization
Conditions:
Male Infertility
Eligibility:
MALE
18+ years
Phase:
NA
Brief Summary
To assess whether the presence of Cytomegalovirus (CMV) Immunoglobulin G (IGG) antibodies in semen is a reliable predictor of male subfertility or infertility.
Detailed Description
Prospective cohort study performed in the artificial reproductive technology (ART) unit. The study will evaluate semen and serum samples from the following groups: 1. Presumably fertile male patient...
Eligibility Criteria
Inclusion
- All male patients addressing the infertility unit in Hadassah Mt Scopus for IVF procedure
Exclusion
- Refusal to participate
- Male partner utilizing pre cycle frozen sperm sample
- Donor sperm cycles
- Surgically retrieved sperm
Key Trial Info
Start Date :
March 2 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2023
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05302856
Start Date
March 2 2022
End Date
March 1 2023
Last Update
August 23 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hadassah Medical Organization
Jerusalem, Israel